Here is a small sampling of the research evidence: A 2012 meta-analysis examined 25 randomized controlled trials and found that GLP-1 receptor agonist treatment caused weight loss
Because GLP-1s are in such high demand, patients who take these drugs for medically necessary reasons can struggle to get their prescriptions filled
Detailed retatrutide scheduling guides can help plan these transitions
Both drugs share common, generally mild-to-moderate gastrointestinal side effects (nausea, vomiting, diarrhea) common to all incretin-based therapies
While strength may not increase dramatically during aggressive fat loss, maintaining or slightly improving numbers indicates successful muscle preservation
Current FDA-approved uses for semaglutide include : Type 2 diabetes management (glycemic control) Cardiovascular risk reduction in type 2 diabetes with established CVD (Ozempic) Cardiovascular risk reduction in adults with established CVD and obesity/overweight (Wegovy) Chronic weight management in obesity or overweight with comorbidities Clinicians should prescribe semaglutide according to FDA-approved indications and established clinical guidelines, including those from the American Diabetes Association (ADA) and American College of Physicians (ACP)